1/7/2019 8:38:12 AM
Mirati Collaborates With Bristol-Myers For Phase 3 Trial In NSCLC To Evaluate Sitravatinib In Combination With Nivolumab
12/10/2018 4:21:45 PM
Mirati Therapeutics Appoints Maya Martinez-Davis To Board Of Directors
11/9/2018 8:51:51 AM
Mirati Reports Preliminary Biomarker Data From Phase 2 Clinical Trial Of Sitravatinib Combined With Nivolumab
11/9/2018 8:44:35 AM
Mirati Announces Data From Phase 2 Trial Of Mocetinostat In Combination With Durvalumab In NSCLC Patients
10/30/2018 9:13:11 AM
Mirati Announces Submission Of IND Application For MRTX849, KRAS G12C Inhibitor, To Treat NSCLC And Colorectal Cancer
10/22/2018 6:10:52 AM
Mirati Therapeutics Presents Updated Positive Clinical Data From Sitravatinib Immuno-Oncology Combination Trial At ESMO
6/7/2018 8:14:37 AM
Mirati Therapeutics Reports Pricing Of Public Offering Of 2.75 Mln Shares At $38.85/Shr
6/6/2018 4:05:04 PM
Mirati Therapeutics Announces Proposed Public Offering Of Common Stock
1/8/2018 6:06:32 AM
BeiGene And Mirati Therapeutics Announce Exclusive License Agreement For Sitravatinib In The Asia Pacific Region
11/4/2016 7:23:37 AM
Wedbush Is Raising Mirati Therapeutics, Inc. (MRTX) Q4 17 Estimate To -0.81 From -0.98
11/4/2016 7:23:26 AM
Wedbush Is Raising Mirati Therapeutics, Inc. (MRTX) Q3 17 Estimate To -0.79 From -0.95
11/4/2016 7:23:16 AM
Wedbush Is Raising Mirati Therapeutics, Inc. (MRTX) Q2 17 Estimate To -0.77 From -0.93
11/4/2016 7:23:06 AM
Wedbush Is Increasing Mirati Therapeutics, Inc. (MRTX) Q1 17 Estimate To -0.76 From -0.91